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Highlights 
 Saw-scaled vipers were shown to have a significant range in clotting times and cofactor dependence. 
 Phospholipid dependence was shown to be inversely correlated with clotting time, suggesting that the 
more effective the enzyme was at using phospholipid, the facter prothrombin was activated 
 Antivenom efficacy was strongly associated with taxonomy, with very little cross-reactivity to venoms 
from more distant species. 
 African antivenom was unable to neutralise non-African species, while Indian antivenom was not able 
to neutralise African species 
Abstract  
Saw-scaled vipers (genus Echis) are one of the leading causes of snakebite morbidity and mortality in 
parts of Sub-Saharan Africa, the Middle East, and vast regions of Asia, constituting a public health burden 
exceeding that of almost any other snake genus globally. Venom-induced consumption coagulopathy, owing 
to the action of potent procoagulant toxins, is one of the most relevant clinical manifestations of envenomings 
by Echis spp. Clinical experience and prior studies examining a limited range of venoms and eected 
antivenoms have demonstrated for some antivenoms an extreme lack of antivenom cross-reactivity between 
different species of this genus, sometimes resulting in catastrophic treatment failure. This study undertook the 
most comprehensive testing of Echis venom effects upon the coagulation of human plasma, and also the 
broadest examination of antivenom potency and cross-reactivity, to-date. 10 Echis species/populations and 
four antivenoms (two African, two Asian) were studied. The results indicate that the venoms are, in general, 
potently procoagulant but that the relative dependence on calcium or phospholipid co-factors is highly variable. 
Additionally, three out of the four antivenoms tested demonstrated only a very narrow taxonomic range of 
effectiveness in preventing coagulopathy, with only the SAIMR antivenom displaying significant levels of 
cross-reactivity. These results were in conflict with previous studies using prolonged preincubation of 
antivenom with venom to suggest effective cross-reactivity levels for the ICP Echi-Tab antivenom. These 
findings both inform upon potential clinical effects of envenomation in humans and highlight the extreme 
limitations of available treatment. It is hoped that this will spur efforts into the development of antivenoms 
with more comprehensive coverage for bites not only from wild snakes but also from specimens widely kept 
in zoological collections. 
Introduction 
Envenoming and deaths resulting from snakebite represent an important public health concern, 
particularly throughout rural areas of South Asia and Sub-Saharan Africa in which access to sufficient 
medical facilities and antivenoms can be limited (Gutiérrez et al., 2006; Kasturiratne et al., 2008; 
Maduwage and Isbister, 2014). It is estimated that snakebite affects around 5 million people and 
accounts for more than 100,000 deaths annually (Chippaux, 1998; White, 2005; Kasturiratne et al., 
2008). However these numbers are dramatic underestimations due to poor or entirely absent 
epidemiological data in many regions. Most severe cases of envenoming are attributed to species 
belonging to the Elapidae and Viperidae families (Gutiérrez et al., 2006). Typically, venoms from 
elapid snakes induce neuromuscular paralysis and are thus classed as neurotoxic, whereas viperid 
snake venoms most commonly target haemostasis (e.g., coagulation dysfunction, fibrinolysis, 
thrombosis) and induce local tissue damage, and are thus broadly categorised as cytotoxic and 
haemotoxic (Boyer et al. 2015; Markland, 1998; Sajevic et al., 2011; Warrell, 2010; White, 2005). 
Coagulopathy, which contributes to sustained bleeding and consequent haemodynamic disturbances 
(Warrell, 2010), is considered to be one of the most common serious systemic clinical pathologies 
induced by snake envenoming (Isbister, 2010). Accordingly, the Viperidae family contains some of 
the most medically significant snake genera worldwide (Gutiérrez et al., 2006; Warrell, 2010). 
Among them, saw-scaled or carpet vipers (Viperidae: Echis) are thought to be responsible for causing 
more snakebite deaths annually than any other genus (Warrell and Arnett, 1976).  
Currently, the genus Echis is thought to comprise at least nine species, distributed across four 
main clades: E. carinatus E. coloratus, E. ocellatus, and E. pyramidum (Pook et al., 2009; Alencar et 
al. 2016). They can be found across the semi-arid and seasonal climate regions of Sub-Saharan Africa 
north of the Equator, Arabia, Iran, Afghanistan and Uzbekistan, and in Pakistan, India and Sri Lanka, 
often in relative abundance. These areas are typically remote, rural, with absent or inadequate medical 
facilities, and with inhabitants of low socio-economic status. This, in conjunction with yielding highly 
toxic venom, renders Echis a common cause of injurious or fatal snakebite in the regions they occupy 
(Habib and Warrell, 2013). Though accurate statistics are sometimes difficult to ascertain due to poor 
documentation of bite cases in such developing nations, Echis ocellatus is responsible for as many as 
95% of snake bites in northern Nigeria, for example (Meyer et al., 1997; WHO 2010a).  Victims are 
most commonly young males, a result of higher encounter rates arising from land cultivation or 
walking (Warrell and Arnett, 1976). In the absence of effective antivenom, case fatality rates 
following envenomation can be as high as 20% even with supportive medical treatment (Warrell and 
Arnett, 1976; Pugh and Warrell, 1980; Visser et al., 2008), and those who survive are often left with 
permanent disability and disfiguring sequelae (Abubakar et al., 2010). Local effects of Echis viper 
envenoming typically include pain, swelling, blistering, and haemorrhage, which, in severe cases, can 
lead to necrosis and amputation. In such cases, the long-term socio-economic impact upon both bite 
victims and their families can be severe and is an often-overlooked consequence of snakebite 
(Vaiyapuri et al., 2013). 
In addition to localised effects, Echis toxins also induce dysfunctions of haemostasis, and 
mortality following envenomation is typically a result of systemic haemostatic disruption, which 
often leads to systemic haemorrhage (Warrell et al., 1977; Boyer et al. 2015). Of the three main 
processes involved in haemostasis (vasoconstriction, platelet plug formation and coagulation (Jin and 
Gopinath, 2016), the majority of snake venoms affecting haemostasis, including those of Echis, target 
the coagulation cascade. The coagulation cascade, whereby blood forms a clot following the stepwise 
activation of multiple clotting factors, requires the presence of Ca2+ ions and platelet-phospholipids. 
These molecules act as co-factors to clotting proteins present in plasma, ultimately inducing the 
proteolytic cleavage of prothrombin to thrombin (Berny et al., 2010; Davie et al., 1991; Jackson and 
Nemerson 1980; Munnix et al., 2007). Then, soluble fibrin monomers are formed by the cleavage of 
fibrinogen by the activated thrombin, and these monomers subsequently form an insoluble fibrin 
meshwork, resulting in a clot (Jin and Gopinath, 2016).  
The snake venom components responsible for perturbing haemostasis are variable, although the 
majority can be classified into four categories according to the part of the coagulation pathway upon 
which they act: factor V activators, factor X activators, prothrombin activators, and thrombin-like 
enzymes (TLEs) or fibrinogenases (Lu et al., 2005; Kini and Koh, 2016; Slagboom et al. 2017). 
Within the genus Echis, the presence of prothrombin activators in species from each of the four main 
clades have been demonstrated (Gillissen et al., 1994; Mann, 1978; Mion et al., 2013; Porath et al., 
1992; Warrell et al., 1977; Yamada et al., 1996). Prothrombin activators found within the genus are 
categorised into two subgroups according to their calcium dependence: ‘ecarin-like’ (Ca2+-
independent) and ‘carinactivase-like’ activators (Ca2+-dependent), classified into groups A and B of 
snake venom prothrombin activators (Kini, 2005). Those belonging to the ‘ecarin-like’ group are 
named so following the discovery of a prothrombin activator (ecarin) with an unprecedented Ca2+-
independent activity, isolated from Echis carinatus venom (Morita and Iwanaga, 1978). In contrast, 
‘CA-like’ activators exhibit Ca2+-dependent activity, e.g., the prothrombin activator carinactivase, 
isolated from Echis leucogaster venom (Yamada et al., 1996). These toxins are responsible for the 
catalysis of prothrombin into thrombin. In natural prey items, this results in rapid subjugation through 
intravascular coagulation leading to cardiovascular collapse. However, in humans, the dilution of the 
venom into a much larger blood volume results in the formation of millions of microthrombi. In and 
of themselves, microthrombi are not lethal, but their formation consumes the majority of available 
essential clotting factors. Clinically, this leads to low or undetectable concentrations of fibrinogen 
(Isbister, 2010) and to multiple blood factor deficiencies, a potentially lethal condition known as 
venom-induced consumption coagulopathy (VICC) (Gillissen et al., 1994; Mann, 1978; Mion et al., 
2013; Porath et al., 1992; Warrell et al., 1977). Coagulopathy also contributes to the generation of 
additional systemic pathologies in human bite victims, including internal haemorrhage, such as 
cerebrovascular accident (Boyer et al. 2015; Warrell et al., 1977). 
Despite envenomation by all Echis species manifesting similar clinical symptoms, previous 
studies have documented considerable inter- and intraspecific variations in their venom composition 
(Barlow et al., 2009; Casewell et al., 2009, 2014; Schaeffer, 1987), apparently driven at least in part 
by natural selection for different diet spectra between the clades (Barlow et al., 2009; Richards et al., 
2012, Savanur et al., 2014). This suggests that variation in the molecular mechanisms inducing these 
pathologies also exists. Such interspecific variation in toxin expression, and therefore in venom 
antigenicity, can greatly affect the ability of an antivenom to neutralise a given venom (Bénard-Valle 
et al. 2015; Fry et al., 2003; Harrison et al., 2003). Antivenoms consist of polyclonal antibodies 
purified from the serum or plasma of animals hyperimmunised with the target species’ venom 
(Bénard-Valle et al. 2015; Heard et al., 1999; Theakston and Warrell, 1991). Due to their polyclonal 
nature, antivenoms are able to neutralise multiple venom components (Gutiérrez et al., 2003; 
Gutiérrez et al 2014); however, the antibodies are specific to the venoms from which they were 
developed (Bénard-Valle et al. 2015). Consequently, while antivenoms are typically marketed as a 
therapeutic treatment for envenomation by a given species, intraspecific venom variation can reduce 
antivenom efficacy, dependent upon the difference between the venom composition of the individuals 
which were used for antivenom manufacture and the individual which delivered the bite (Bénard-
Valle et al. 2015; Boyer et al. 2015). It is well documented that the success rates achieved by different 
antivenoms in treating Echis snakebites can vary significantly depending on the geographical location 
of the bite due to regional variation of the species’ venom (Abubakar et al., 2010; Calvete et al., 2016; 
Casewell et al., 2010), which can translate into catastrophic treatment failure and case fatality rates 
increased by an order of magnitude in a tropical clinical setting (Alirol et al. 2015; Visser et al., 2008; 
Warrell and Arnett, 1976; Warrell et al. 1980).  
In light of the complications associated with Echis envenomings, from a clinical perspective, 
there is a distinct need to characterise the coagulant activity of venoms of this genus, with particular 
reference to geographical variation, and to explore the implications this may have for antivenom 
cross-reactivity. In this study, a comparative analysis of the venoms of six representative species 
belonging to the four main clades of Echis was conducted. Coagulation assays were used to explore 
the interspecific and intraspecific variations of coagulopathic toxicity within Echis. Antivenom cross-
reactivity was investigated by comparing the neutralising capacity of four Echis antivenoms. This 
research has been conducted to provide the first comprehensive reference framework for Echis venom 
coagulopathic effects and differential response to antivenoms.  
Materials and Methods 
Venom samples 
A total of ten Echis pooled-venom samples were included in this study, comprising six 
representative species belonging to the four main clades of the genus and from across its geographical 
distribution. The venoms were sourced from the cryogenic venom collection of the Venom Evolution 
Lab, University of Queensland and that of the Alistair Reid Venom Research Unit, Liverpool School 
of Tropical Medicine. Species and localities were as follows: E. carinatus (India), E. c. sochureki 
(Mithi, Tharparkar District, Sindh Province, Pakistan), E. c. sochureki (United Arab Emirates), E. 
coloratus (Saudi Arabia), E. jogeri (Bandafassi, Kédougou Region, Senegal), E. leucogaster (Mali), 
E. ocellatus (Ghana), E. ocellatus (Mali), E. ocellatus (Nigeria), and E. pyramidum leakeyi (Kenya). 
Pooled samples were used to account for any potential venom variation between individuals due to 
such variables as sex and age. Working stock solutions from freeze-dried venom were reconstituted 
to a concentration of 1mg/ml in 50% deionised water / 50% glycerol (Sigma-Aldrich) to prevent 
freezing and thus reduce enzyme degradation and preserve enzymatic activity. Working stocks were 
stored at -20°C and used for all subsequent analyses. 
Human plasma  
Human plasma was provided by the Australian Red Cross (44 Musk Street, Kelvin Grove, 
Queensland 4059). Three batches of pooled plasma (Lot#4456062 (Rhesus A+), Lot#4439715 
(Rhesus A-), Lot#4439719 (Rhesus O-)) were further pooled and aliquoted. The plasma aliquots were 
then flash frozen in liquid nitrogen and stored at -80°C until use. For all coagulation analyses, plasma 
aliquots were defrosted in an Artic refrigerated circulator SC150-A40 for 5 minutes (min) at 37°C 
and immediately used for experimentation.  
Coagulation analyses  
Coagulation analyses were performed on a Stago STA-R Max® automated coagulation 
analyser (Stago, Asnières sur Seine, France) using Stago Analyser software v0.00.04 (Stago, Asnières 
sur Seine, France). To check the quality of the plasma, positive and negative controls were conducted 
and compared to pre-established plasma clotting parameters in the presence and absence of an 
activator (49-51 seconds (s) and 450-550 s respectively). The positive control was conducted by 
performing a standardised activated Partial Thromboplastin Time (aPTT) test (Stago Cat#T1203 
TriniCLOT APTT HS). 50 µL Kaolin (STA C.K.Prest standard kit, Stago Cat#00597), a coagulation 
activator, was added to 50 µL plasma and incubated for 120 seconds. 50 µL CaCl2 (0.025 M, Stago 
Cat#00367) was then added, and time until clot formation was measured. As a negative control, test 
conditions in the absence of venom were replicated. 50 µL buffer solution (30 µL 50% deionised H2O 
/ 50% glycerol in 270 µL Owren-Koller (OK) buffer) was added to 50 µL CaCl2, 50 µL phospholipid 
and 25 µL OK buffer, and then incubated for 120 s at 37°C. 75 µL plasma was then added and clotting 
time measured. Both controls were run in triplicate before commencing any venom analyses.  
In order to determine clotting times effected by the addition of varying venom concentrations, 
venom working stock solution was diluted with Owren Koller (OK) Buffer (Stago Cat# 00360) as 
appropriate in order to perform 10-point dilution series (µg/ml: 20, 10, 5, 2.5, 1.33, 0.66, 0.4, 0.2, 0.1, 
and 0.05). 50 µL of CaCl2 with 50 µL phospholipid (cephalin prepared from rabbit cerebral tissue 
from STA C.K Prest standard kit, Stago Cat# 00597, solubilised in OK Buffer) were added to 50 µL 
of the diluted venom. An additional 25 µL of OK Buffer was added to the cuvette and incubated for 
120 seconds at 37°C before adding 75 µL human plasma (total volume 250 µL /cuvette). Time until 
clot formation was then immediately monitored by the automated analyser. Tests were conducted in 
triplicate, with plasma and venom being replaced every 15-30 minutes to minimise enzyme 
degradation.  
Phospholipid and calcium dependence  
In order to test for co-factor dependence of the venoms, the aforementioned coagulation 
analyses were run both with and without CaCl2 and/or phospholipid. The experimental protocol was 
identical, with the exception that 50 µL OK Buffer was added as a substitute for the removed co-
factor to ensure consistency in final test volumes (250 µL). Tests were conducted in triplicate, with 
plasma and venom being replaced every 15-30 minutes to minimise enzyme degradation.  
Antivenom tests 
The relative efficacy of four polyvalent and monovalent antivenoms were investigated in this 
study. The previously measured whole plasma clotting times for each venom were used as a guide 
for antivenoms effects. Four antivenoms were assessed; three polyvalent: (a) EchiTAb-Plus-ICP, 
from Instituto Clodomiro Picado, Costa Rica (Lot 5620715PALQ), (b) Sii Polyvalent Anti-snake 
Venom Serum from Serum Institute Of India LTD, India (Lot 045D0004), and (c) Snake Venom 
Antiserum I.P. from VINS Bioproducts LTD, India (Lot 1081); and one monovalent: SAIMR Echis 
antivenom provided by South African Vaccine Producers (SAVP) (South Africa – Lot 2147)  (Table 
1). 
Antivenoms which were provided in lyophilised form were reconstituted in sterile water (if 
indicated by the manufacturer), aliquoted, and stored at 4°C. In order to ascertain the potency, as each 
antivenom vial contained the same final volume (10ml) equal volumes of each antivenom were used 
for testing. For antivenom testing, all test conditions replicated that of the coagulation analyses, with 
the exception that 25µl of antivenom working solution (50 µL reconstituted antivenom in 950 µL OK 
buffer) used in place of 25µl of OK Buffer: 50 µL venom, 50 µL calcium, 50 µL phospholipid, 25 
µL antivenom, 120 s incubation time, 75 µL plasma. Time until clot formation was then immediately 
measured. Experiments were conducted in triplicate, with plasma and venom being replaced every 
15-30 minutes to minimise enzyme degradation.  
Statistical analysis 
Coagulation times (seconds) for each of the venoms and antivenoms were graphed using Prism 7.0 software 
(GraphPad Software Inc, La Jolla, CA, USA) to produce concentration response curves. Calculation of EC50 
(concentration of venom at which 50% of the effect is observed) values for the venom and antivenom 
concentration curves for each dataset were performed using Prism 7.0 software (GraphPad Software Inc, La 
Jolla, CA, USA). Data is expressed as mean ± SD. After EC50s were calculated, the relative antivenom efficacy 
was calculated using the formula: 
x=abc/def-1 with a= antivenom EC50 x-axis, b= antivenom EC50 y-axis, c= antivenom starting clotting time, 
d= venom EC50 x-axis, e= venom EC50 y-axis and  f= venom starting clotting time. 
The phylogenetic tree used was based upon a previously published species tree (Pook et al., 2009; Alencar et 
al. 2016) and created using Mesquite software (version 3.2), which was then imported into Rstudio using the 
APE package (Paradis et al., 2004). Ancestral states were estimated for all traits (including the proportional 
shift of the relative co-factor dependence and relative antivenom efficacy) using maximum likelihood as 
implemented in the contMap function of the R package phytools (Revell, 2012). We then fit pGLS models 
(Symonds and Blomberg, 2014) in caper (Orme et al., 2015) to test for relationships. Specific scripts for each 
step in R are as follows: 
PHYTOOLS CODE 
>library(ape) 
>library(maps) 
>library(phytools) 
> # senci.contMap is a slight modification of errorbar.contMap that trims 95% CIs of ancestral state reconstructions to a 
sensible range, e.g. for traits bound between 0 and 1 
# Example of code for implementing it would be as follows (lines separated by semicolons): pasr<-
contMap(tree,mapdat,plot=F,lims=c(0,1)) ; plot(setMap(pasr,invert=T)) ; 
senci.contMap(setMap(pasr,invert=T),mini=0,maxi=1) 
senci.contMap<-function(obj,...){ 
if (hasArg(x))  
        x <- list(...)$x 
    else x <- setNames(sapply(1:Ntip(obj$tree), function(x, obj) { 
        ii <- which(obj$tree$edge[, 2] == x) 
        ss <- names(obj$tree$maps[[ii]][length(obj$tree$maps[[ii]])]) 
        obj$lims[1] + as.numeric(ss)/(length(obj$cols) - 1) *  
            diff(obj$lims) 
    }, obj = obj), obj$tree$tip.label) 
    if (hasArg(scale.by.ci))  
        scale.by.ci <- list(...)$scale.by.ci 
    else scale.by.ci <- TRUE 
    if (hasArg(lwd))  
        lwd <- list(...)$lwd 
    else lwd <- 14 
    tree <- obj$tree 
    aa <- fastAnc(tree, x, CI = TRUE) 
if (hasArg(min))#added lines here 
for (i in 1:length(aa$CI95[,1])){ #added lines here 
    aa$CI95[i,1]<-ifelse(aa$CI95[i,1]<list(...)$min,list(...)$min,aa$CI95[i,1]) #added lines here 
    } #added lines here 
else aa$CI95[,1]<-aa$CI95[,1] #added lines here 
if (hasArg(max)) #added lines here 
for (i in 1:length(aa$CI95[,2])){ #added lines here 
    aa$CI95[i,2]<-ifelse(aa$CI95[i,2]>list(...)$max,list(...)$max,aa$CI95[i,2]) # added lines here 
    } #added lines here 
else aa$CI95[,2]<-aa$CI95[,2] #added lines here 
    xlim <- range(aa$CI95) 
    if (xlim[2] > obj$lims[2] || xlim[1] < obj$lims[1]) { 
        cat(paste("  -----\n  The range of the contMap object, presently (",  
            round(obj$lims[1], 4), ",", round(obj$lims[2], 4),  
            "), should be equal to\n  or greater than the range of the CIs on ancestral states: (",  
            round(xlim[1], 4), ",", round(xlim[2], 4), ").\n",  
            sep = "")) 
        cat(paste("  To ensure that your error bars are correctly plotted, please recompute your\n",  
            "  contMap object and increase lims.\n  -----\n",  
            sep = "")) 
    } 
    d <- diff(obj$lims) 
    if (scale.by.ci) { 
        v <- aa$CI95[, 2] - aa$CI95[, 1] 
        v <- v/max(v) 
    } 
    else v <- rep(0.5, tree$Nnode) 
    n <- length(obj$cols) - 1 
    lastPP <- get("last_plot.phylo", envir = .PlotPhyloEnv) 
    h <- max(nodeHeights(tree)) 
    for (i in 1:tree$Nnode) { 
        ii <- round((aa$CI95[i, 1] - obj$lims[1])/d * n) 
        jj <- round((aa$CI95[i, 2] - obj$lims[1])/d * (n + 1)) 
        cols <- obj$cols[ii:jj] 
        add.color.bar(leg = 0.1 * h * v[i], cols = cols, prompt = FALSE,  
            x = lastPP$xx[i + Ntip(tree)] - 0.05 * h * v[i],  
            y = lastPP$yy[i + Ntip(tree)], title = "", subtitle = "",  
            lims = NULL, lwd = lwd) 
    } 
} 
>data<-read.csv(file.choose())  
>dat<-data 
>mapvar<-dat$var 
>names(mapvar)<-dat$species 
>tree<-read.tree(file.choose())  
>tree<-chronos(tree) 
>asr<-contMap(tree,mapvar,plot=F) 
For red (warmer) zone for the higher numbers (eg antivenom shifts) the below was used.  
>plot(setMap(asr,col=c(1,4,5,3,7,2,6,8))) 
>senci.contMap(setMap(asr,col=c(1,4,5,3,7,2,6,8)),min=x,max=y) 
For red (warmer) zone for smaller numbers (eg clotting time and co factors) the below was used 
>plot(setMap(asr,col=c(8,6,2,7,3,5,4,1)),lwd=10) 
>senci.contMap(setMap(asr,col=c(8,6,2,7,3,5,4,1)),min=x,max=y) 
In both cases, the x and y for senci were the low and high numbers (respectively) for the particular dataset. 
PHYLOGENETIC GENERALISED LEAST SQUARES REGRESSION (PGLS) STEP 
>library(caper)  
>data<-read.csv(file.choose())  
>tree<-read.tree(file.choose())  
>com<-comparative.data(tree,data,species)  
For values of variable range in the responder column, these steps were used 
>mod<-pgls(var1~var2,com,lambda="ML")  
>summary(mod) 
For 0 to 1 values in the responder column 
>mod<-pgls(57.295*asin(sqrt(var1))~var2,com,lambda="ML") 
>summary(mod) 
Results and Discussion 
Procoagulant activity was revealed to be a dynamic feature without a strong phylogenetic pattern, and 
also without any obvious relationship with the diet spectra of the clades, despite diet-specific differences in 
venom lethality to prey (Barlow et al., 2009), therefore suggesting this is a dynamic ancestral functional 
phenotype in Echis spp. Testing revealed all venoms to follow a similar dilution curve trajectory. However, 
clotting times at maximal venom concentration (20 µg/mL) varied from 19.53+/-1.30s for E. pyramidum 
leakeyi to 40.13+/-1.20s for E. carinatus (India), though most venoms induced a clot in around 20-25 seconds 
(Figure 1, Table 2). Only E. carinatus (India) and E. leucogaster (Mali) venoms took longer than 30 s to 
generate a clot (Figure 1). There was significant variation in clotting time within each of the three major clades. 
E. carinatus (India) was significantly slower than the two other venoms in the E. carinatus clade (E. c. 
sochureki (Pakistan) and E. c. sochureki  (UAE), but with E. c. sochureki (Pakistan) and E. c. sochureki (UAE) 
not differing significantly from each other. E. leucogaster was also significantly slower than its closest 
relatives in this study (E. coloratus and E. pyramidum leakeyi), with E. coloratus and E. pyramidum leakeyi 
also being significantly different in their clotting times relative to each other. Within the E. jogeri/E. ocellatus 
clade all venoms differed significantly from each other, with coagulant activity for the four venoms ranging 
from 19.63s (E. jogeri (Senegal)) to 27.0s (E. ocellatus (Ghana)). 
The interspecific variation in calcium cofactor dependence showed a strong phylogenetic pattern and 
varied from the almost independent E. carinatus (India locale), with a clotting time shift of only 0.42 +/- 0.02-
fold in the absence of calcium, to total dependence in E. coloratus (Saudi Arabia), which was unable to induce 
a clot in the instrument’s maximum measurement time range (999 s) and thus has a clotting time shift of at 
least 17.5-fold (Figure 2, Table 2). The basally split E. carinatus clade ranged from strong to moderate calcium 
independence. The E. jogeri/E. ocellatus clade displayed consistent strong calcium-independence. In contrast, 
all venoms from the E. pyramidum clade exhibited a high degree of calcium dependence. Taken in the context 
of the phylogeny (Figure 2) this suggests that low levels of calcium dependence is the plesiotypic condition of 
the Echis genus.   
In contrast to the extreme effect seen with regard to calcium cofactor dependence, relative shifts in 
clotting time in the absence of additional phospholipid cofactor were substantially less than those of calcium, 
and also lacked the strong phylogenetic pattern evident for calcium dependence (Figure 2, Table 2). Relative 
phospholipid dependence ranged from 0.04 +/- 0.01-fold for E. carinatus (India) through to 0.90 +/- 0.07-fold 
for E. c. sochureki (Pakistan). The third member of this clade, E. sochureki (UAE locale; 0.48 +/- 0.03-fold) 
demonstrated intermediate dependence. The other clades were also variable. Thus, while phospholipid 
dependence in general was less pronounced, the lack of phylogenetic consistency suggests that it is a labile 
character relative to that of calcium dependence.  
A higher relative degree of calcium dependence predicted increased relative phospholipid dependence 
(PGLS: t=2.2734, p=0.03851), but the reverse was not true in that the relative degree of phospholipid 
dependence did not predict that of calcium dependence (PGLS: t=1.6467, p=0.13824). This may suggest that 
changes in calcium dependence subsequently lead to changes in phospholipid dependence, but this directional 
suggestion remains tentative. Higher relative degree of phospholipid dependence was associated with faster 
clotting times, though this effect was marginally non-significant (PGLS: t=-2.1562, p=0.063160) (Figure 3). 
In contrast, the relative calcium dependence did not predict clotting time (PGLS: t=-1.7817, p=0.11266). Thus 
there appears to be a positive correlation between the ability of the enzymes to use phospholipid and their 
ability activate prothrombin, which is consistent with neofunctionalisation of these enzymes for such an 
activity relative to their ancestral protease activity. Thus the more the enzymes are able to utilize phospholipid 
for the newly evolved prothrombin activation activity, the faster the reaction proceeds. The structural features 
responsible for this phospholipid utilisation are unknown and thus represent a rich area of future research. The 
dynamic nature of this in relationship to the phylogeny of the snakes themselves is a particularly fascinating 
riddle (Figure 2). Additional studies are required however to confirm this directionality and the biochemical 
mechanisms behind it. 
The four antivenoms tested using equal volumes of each antivenom had extremely variable results both 
in potency and species targeted (Figures 4-7, Tables 3 and 4). EchiTAb-Plus-ICP antivenom had the strongest 
effect of all the antivenoms tested in this study, being for example twice as effective as SII in relation each 
antivenom’s best neutralised venom but not to the 6.6-fold ratio that may be anticipated from the package 
insert details (Table 1). Consistent with E. ocellatus venom being used in the immunising mixture, this 
antivenom demonstrated strong selectivity for the West African species E. ocellatus venoms and, to a lesser 
extent, the E. jogeri venom. The strongest effect was seen for E. ocellatus (Ghana) venom which had the 
clotting curve proportionally shifted with an effect of 65-fold. The other E. ocellatus populations were also 
well neutralised, but to a lesser extent. Unexpectedly, of the E. ocellatus samples tested, the population from 
Nigeria was the least affected by the EchiTab-ICP, despite the antivenom being manufactured from pooled 
venoms of E. ocellatus collected from Nigeria (Gutiérrez et al., 2005). While the precise locality of the 
Nigerian sample used in this study was not known, the results never-the-less indicative of geographical or 
individual variation within the region and follow-up studies should investigate this matter further. The 
antivenom also significantly shifted the clotting curve of E. jogeri. However, despite showing good efficacy 
for this clade, the EchiTab-ICP had little effect upon the other venoms thus demonstrating a narrow taxonomic 
range of efficiency.  
In discordance with these findings (Figures 4-7, Tables 3 and 4), a previous study described the ability 
of the ICP antivenom to neutralise coagulant activity of the venoms of E. pyramidum and E. leucogaster 
(Segura et al., 2010). This discrepancy is likely to be attributable to differences in experimental protocol. 
Segura et al. (2010) used a more prolonged incubation time (30 minutes incubation) as compared to the 
protocol used in the present study (2 minutes incubation). Longer incubation times would likely conceal 
differences in efficacy between venom/antivenom pairs as slower, weaker binding combinations would have 
time to reach the levels more quickly obtained by faster, stronger binding combinations. The traditional 
protocols to assess the neutralizing ability of antivenoms at the preclinical level involve the incubation of 
venom and antivenom for 30 min or even for one hour before testing [see for example Christensen 1955, 
Bolaños 1977, and WHO 1981]. Moreover, the 30 min incubation protocol at 37 °C is indicated in the current 
version of the official WHO guidelines for antivenom production and quality control (WHO, 2010).  In 
contrast, the new protocol used in this study introduces a more rigorous evaluation of the neutralizing capacity 
of antivenoms by reducing the incubation time to 2 min, thus demanding high affinity antibodies for the 
neutralization while also ascertaining the ability of the antivenoms to neutralise the coagulopathic enzymatic 
activity. 
Consistent with E. pyramidum (Ethiopia/Eritrea) and E. ocellatus (Nigeria) venoms being used in the 
immunising mixture, the SAIMR antivenom had the strongest selectivity for the species within the E. 
pyramidum clade but also displayed significant cross-reactivity for E. ocellatus venoms as well as the E. jogeri 
venom from the same clade (Figures 4-7, Tables 3 and 4). Thus our results confirm that the SAIMR antivenom 
is effective against both East and West African Echis species and while it may require more antivenom for the 
treatment of West African species it clearly has the broadest coverage of African Echis species (Figures 4-7).  
Neither Indian antivenom was able to neutralise the Indian-locale venom samples included in this study 
(Figures 4-7, Tables 3 and 4). While both antivenoms use the Chennai population of E. carinatus in the 
immunising mixture, the geographical locality within India for the venom used in this study is unknown. 
However, this clearly points to potential intra-country clinical issues and this disparity should be the focus of 
an urgent follow-up study as this country is notable for such variation (Kochar et al. 2007). The SII antivenom 
performed well against the Pakistan E. c. sochureki population and to a lesser but still significant extent, the 
UAE E. c. sochureki population. Despite having a package insert stated potency equivalent to that of SII (Table 
1), the VINS antivenom performed comparatively poorly with values comparable with the low-level cross-
reactivity of EchiTAb-Plus-ICP and SAIMR for the Pakistan and UAE E. c. sochureki populations. Both the 
SII and VINS antivenoms give the same stated neutralising ability against the lethal effect of venoms when 
tested through the historical method of 30 min preincubation of antivenom with venom and then injection of 
the mixture into mice (Table 1). However, their performance was markedly different in this study regarding 
ability to neutralize the coagulant activity (Tables 3 and 4). Thus the VINS antivenom can be predicted to have 
little or no likely clinical usefulness against the South Asian or African venoms tested in this study without 
requiring extremely large doses relative to the other antivenoms studied. These findings agree with a previous 
study showing that VINS antivenom is highly inefficient in the neutralisation of E. ocellatus from Cameroon 
(Calvete et al., 2016). 
Our findings demonstrate that there is gradated calcium dependence throughout the genus (Figure 2). 
This presents an intriguing example of venom variability and one with profound clinical implications. As the 
procoagulant activity of Echis spp. venoms is driven by prothrombin activating SVMPs, the calcium 
dependency (Figure 2) may shed light on the type of predominant type in each. Prothrombin activating SVMP 
are divided into Class A (calcium independent) and Class B (calcium dependent) (Casewell et al. 2015; Kini 
and Koh, 2016). These functional/structural divisions are sometimes referred to as ecarin-like or carinativase-
like based upon the first of each type described for each. These functional classes are also reflective of 
structural differences, with the monomeric P-IIIa SVMP making up Class A while Class B is a P-IIIa SVMP 
non-covalently linked to a lectin dimer (with the two lectin subunits covalently linked to each other) (Yamada 
et al. 1996; Casewell et al. 2015). This trimer differs from the classical P-IIId SVMP which are covalently 
linked to a lectin dimer (Casewell et al. 2015). As low levels of calcium dependence is the plesiotypic state 
(Figure 2), this suggests that the evolution of a monomeric calcium independent P-IIIa SVMP preceded the 
evolution of the apotypic trimeric calcium dependent P-III. The reasons for the requirement for calcium due 
to the structural derivation in the P-III SVMPs remains to be elucidated and highlights an area for future 
research. However, due to the structural differences in the two functional classes, the venoms used in the 
antivenom immunising mixture may bias the antivenom efficacy towards dependent or independent venom 
types and thus may be responsible in part for the extreme clade-specific antivenom effects in combination with 
diversification of the physico-chemical properties of the prothrombin activating SVMP toxins responsible for 
the lethal effects.  
This study has demonstrated that the antivenoms were highly variable not only in comparative potency 
in neutralising procoagulant activity, but also in relative species selectivity (Figures 4-7, Tables 3 and 4). The 
most potent antivenom (EchiTAb-Plus-ICP) also displayed the extremely narrow species selectivity. Although 
procoagulant activity is not the sole mode of action of Echis venoms it does play a key role in lethality. Our 
results indicate that the different Echis antivenoms tested are of greatest usefulness for neutralisation of this 
activity within the clade of venoms from which the immunising venom was drawn, with limited regional cross-
reactivity. This suggests that, in at least the case of Echis, phylogenetic affinities can be used as a roadmap for 
the selection of antivenoms to test for effectiveness for unstudied populations, and, in an emergency, for the 
treatment of bites by captive specimens, although other factors may also play a role (e.g., Gillissen et al., 1994). 
This underscores the importance of phylogenetic and systematic studies as a guide for antivenom design and 
testing in this genus (Fry et al., 2003; Williams et al., 2011).    
The results of this study demonstrating very narrow taxonomic efficacy ranges (Figure 7) are in conflict 
with previous studies, which suggested much broader efficacy ranges but involved much longer (15x) 
incubation times of antivenom-venom mixtures and a protocol that selected for ability to impede lethality 
rather than directly measuring impedence of lethality  (Warrell et al. 1980; Casewell et al., 2010; Segura et al. 
2010). Future work should be undertaken to investigate whether the prolonged venom:antivenom pre-
incubation times used as standard in preclinical testing (WHO, 2010b) are actually predictive of clinical 
efficacy. Venom binding by the antivenom under such idealised circumstances may not necessarily reflect 
what occurs in a clinical setting. Venom and antivenom interactions in the body are due to opportunistic 
encounters in a dynamic system. Thus the longer incubation times historically used in preclinical testing would 
allow time for low-affinity antibodies to bind as they are in forced proximity with the venom for biologically 
unrealistic period of time. Conversely the shorter incubation times used in this study may in fact better reflect 
the real-world opportunity for venom binding by the high affinity antibodies in the antivenom. Such 
considerations will however require rigorous future studies to resolve these important questions. 
In conclusion, this study has revealed extreme cross-reactivity issues for Echis antivenoms (Figures 4-
7) and highlights the urgent need for the development of cost-effective, pan-regional antivenoms for Africa 
and Asia that cover all the Echis venom clades in their corresponding continents. Moreover, the Mid-East 
region and Arabian Peninsula contain species from three of the four Echis clades, including the south Asian 
carinatus group (E. carinatus sochureki), the Arabian coloratus group (E. coloratus, E. omanensis) and the 
African pyramidum clade (E. borkini, E. khosatzkii). Consequently, there is a clear need to test antivenoms 
used in the region for efficacy against all relevant venoms using the biologically relevant incubation times in 
the protocol of this study. Further, there may be also a need for a combined African/Asian Echis antivenom. It 
is hoped that these results will stimulate such life-saving efforts. The results of our study are of particular 
immediate concern as some manufacturers are selling their products outside the region from which the 
immunising venom was obtained and this unscrupulous marketing of non-regional specific antivenoms has 
resulted, in some cases, in an over twenty-fold increase in fatality rate (Alirol et al. 2015; Visser et al., 2008; 
Warrell 2008). 
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Table 1: Antivenoms studied 
Antivenom 
 
Stated species coverage. Stated neutralising 
capacity (per mL 
antivenom) 
EchiTAb-Plus-ICP, 
Instituto Clodomiro Picado, 
Costa Rica; Lot 
5620715PALQ.  
Equine whole IgG; specific Echis 
ocellatus, Bitis arietans and Naja 
nigricollis (Nigerian locality) 
No less than 3.0 mg E. 
ocellatus venom 
Sii Polyvalent Anti-snake 
Venom Serum, Serum 
Institute Of India LTD, 
India; Lot 045D0004. 
Equine F(ab’)2; specific Echis 
carinatus, Daboia russelli, Naja 
naja and Bungarus caeruleus. 
No less than 0.45 mg of E. 
carinatus venom 
Snake Venom Antiserum 
I.P., VINS Bioproducts 
LTD, India; Lot 1081. 
Equine F(ab’)2; specific Echis 
carinatus, Daboia russelli, Naja 
naja and Bungarus caeruleus. 
No less than 0.45 mg of E. 
carinatus venom 
SAIMR Echis pyramidum 
leakeyi antivenom, South 
African Vaccine Producers 
(SAVP), South Africa; Lot 
NO2147. Note the insert 
says E. carinatus but this is 
reflective of outdated 
taxonomy. Immunising 
venom mixture has been a 
combination Echis 
pyramidum specimens from 
Ethiopia/Eritrea and E. 
ocellatus from Nigeria 
(Priscilla Fleisher, SVAP 
personal communication) 
Equine F(ab’)2; specific Echis 
carinatus, paraspecific Echis 
coloratus 
Not stated 
 
  
Table 2: clotting times and co-factor influence 
Species 
20µg/ml clotting 
time (seconds) 
Calcium 
dependence* 
Phospholipid 
dependence* 
Echis carinatus carinatus (India) 40.13+/-1.20 0.42+/-0.02 0.04+/-0.01 
Echis carinatus sochureki (Pakistan) 20.83+/-0.77 4.07+/-0.01 0.90+/-0.07 
Echis carinatus sochureki (UAE) 21.60+/-0.96 3.4+/-0.04 0.48+/-0.03 
Echis coloratus (Saudi Arabia) 26.86+/-0.15 >17.5 0.70+/-0.19 
Echis jogeri (Senegal) 19.63+/-0.32 1.05+/-0.01 0.32+/-0.08 
Echis leucogaster (Mali) 38.77+/-1.8 9.67+/-0.04 0.29+/-0.05 
Echis ocellatus (Ghana) 27.90+/-1.30 1.01+/-0.01 0.33+/-0.02 
Echis ocellatus (Mali) 22.83+/-1.79 0.80+/-0.04 0.17+/-0.05 
Echis ocellatus (Nigeria) 24.67+/-1.36 1.18+/-0.07 0.44+/-0.03 
Echis pyramidum leakeyi (Kenya) 19.53+/-1.30 7.73+/-0.36 0.63+/-0.07 
 
*Co-factor dependence is the proportional shift in 20µg/ml clotting time without the presence of the co-
facor.   
Table 3: Relative potency for each antivenom. Values indicate x–fold shift in clotting curves 
Species ICP SAIMR SII VINS 
Echis carinatus carinatus (India) 0.34+/-0.01 0.91+/-0.02 1.36+/-0.041 0.42+/-0.04 
Echis carinatus sochureki (Pakistan) 6.97+/-0.17 9.09+/-0.29 29.91+/-0.19 8.74+/-0.28 
Echis carinatus sochureki (UAE) 3.71+/-0.04 6.57+/-0.22 16.08+/-1.10 4.67+/-0.21 
Echis coloratus (Saudi Arabia) 1.39+/-0.29 21.75+/-2.61 2.21+/-0.21 1.21+/-0.42 
Echis jogeri (Senegal) 25.95+/-0.13 7.52+/-0.03 3.35+/-0.01 1.85+/-0.01 
Echis leucogaster (Mali) 2.07+/-0.55 22.58+/-0.40 1.55+/-0.24 0.35+/-0.01 
Echis ocellatus (Ghana) 64.40+/-1.16 14.35+/-0.50 0.75+/-0.05 0.50+/-0.07 
Echis ocellatus (Mali) 44.48+/-1.34 11.27+/-0.081 0.52+/-0.04 0.52+/-0.11 
Echis ocellatus (Nigeria) 34.28+/-0.56 14.40+/-0.26 2.13+/-0.08 1.71+/-0.66 
Echis pyramidum leakeyi (Kenya) 1.04+/-0.11 21.54+/-0.57 7.16+/-0.50 2.38+/-0.08 
 
  
Table 4: Pairwise comparison in antivenom efficacy*. 
Antivenom pairs Eca-I Ecs-P Ecs-U Eco-S Ejo-S 
ICP vs. SAIMR <0.0001 <0.0001 0.0012 <0.0001 <0.0001 
ICP vs. SII <0.0001 <0.0001 <0.0001 0.8708 <0.0001 
ICP vs. VINS 0.0169 <0.0001 0.24 0.9983 <0.0001 
SAIMR vs. SII <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
SAIMR vs. VINS <0.0001 0.3637 0.0151 <0.0001 <0.0001 
SII vs. VINS <0.0001 <0.0001 <0.0001 0.7943 <0.0001 
 
Antivenom pairs Ele-M Eoc-G Eoc-M Eoc-N Epl-K 
ICP vs. SAIMR <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
ICP vs. SII 0.3659 <0.0001 <0.0001 <0.0001 <0.0001 
ICP vs. VINS 0.0017 <0.0001 <0.0001 <0.0001 0.0112 
SAIMR vs. SII <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
SAIMR vs. VINS <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
SII vs. VINS 0.0146 0.9594 >0.9999 0.3898 <0.0001 
* p-values from Tukey's multiple comparisons test 
Eca-I = E. carinatus (India), Ecs-P = E. c. sochureki (Pakistan), Ecs-U = E. c. sochureki (UAE), Eco-S = E. 
coloratus (Saudi Arabia), Ejo-S = E.jogeri (Senegal), Ele-M = E. leucogaster (Mali), Eoc-G = E. ocellatus 
(Ghana), Eoc-M = E. ocellatus (Mali), Eoc-N = E. ocellatus (Nigeria), Epl-K = E. pyramidum leakeyi (Kenya).  
  
Figure 1: A) Venom dose-response curves with values of means from N=3 with error bars indicating standard 
deviation (error bars at most concentrations are smaller than the symbols), and B). Ancestral state 
reconstruction of clotting times, where warmer colours represent faster clotting times. Bars indicate 95% 
confidence intervals for the estimate at each node. Note that due to the high dynamicity of venom evolution 
the ranges quickly become broad as one moves down the tree. Numbers at tips are means of N=3 maximum 
clotting times from (A) (Table 2). Phylogenetic tree is based upon (Pook et al., 2009; Alencar et al. 2016). 
  
Figure 2: Ancestral state reconstruction of relative co-factor dependence, where warmer colours represent 
greater cofactor dependence. Bars indicate 95% confidence intervals for the estimate at each node. Note that 
due to the high dynamicity of venom evolution the ranges quickly become broad as one moves down the tree. 
Numbers at tips are means from N=3 tests for x-fold shift in clotting time (Table 2). Phylogenetic tree is based 
upon (Pook et al., 2009; Alencar et al. 2016). 
 
  
Figure 3: Ancestral state reconstructions to show the inverse relationship between procoagulant activity 
(where warmer colours represent faster clotting times) and phospholipid cofactor dependence (where warmer 
colours indicate greater degree of dependence). Bars indicate 95% confidence intervals for the estimate at each 
node. Note that due to the high dynamicity of venom evolution the ranges quickly become broad as one moves 
down the tree. Numbers at tips are means from N=3 tests for x-fold shift in clotting time and phospholipid 
dependence (Table 2). Phylogenetic tree is based upon (Pook et al., 2009; Alencar et al. 2016). 
  
 Figure 4: Coagulation dose-response curves. Blue lines represent venom in optimal conditions (i.e. with 
calcium and phospholipid) while red line represents the clotting activity remaining after 2 minute preincubation 
of venom with antivenom and then the same dilution series were run as for the blue line protocol. The 
antivenom remained a constant in the second protocol while the venom was diluted against it as per the X-axis 
concentrations (µg/ml). The y-axis is time (seconds). Values are means from N=3 with error bars indicating 
standard deviation. Eca-I = E. carinatus (India), Ecs-P = E. c. sochureki (Pakistan), Ecs-U = E. c. sochureki 
(UAE), Eco-S = E. coloratus (Saudi Arabia), Ejo-S = E.jogeri (Senegal), Ele-M = E. leucogaster (Mali), Eoc-
G = E. ocellatus (Ghana), Eoc-M = E. ocellatus (Mali), Eoc-N = E. ocellatus (Nigeria), Epl-K = E. pyramidum 
leakeyi (Kenya).  
 
Figure 5: Normalised logarithmic transformed views of clotting effects. Blue lines represent venom in optimal 
conditions (i.e. with calcium and phospholipid) while red line represents the clotting activity remaining after 
2 minute preincubation of venom with antivenom and then the same dilution series were run as for the blue 
line protocol. The antivenom remained a constant in the second protocol while the venom was diluted against 
it. Values are means from N=3 with error bars indicating standard deviation. Eca-I = E. carinatus (India), Ecs-
P = E. c. sochureki (Pakistan), Ecs-U = E. c. sochureki (UAE), Eco-S = E. coloratus (Saudi Arabia), Ejo-S = 
E.jogeri (Senegal), Ele-M = E. leucogaster (Mali), Eoc-G = E. ocellatus (Ghana), Eoc-M = E. ocellatus (Mali), 
Eoc-N = E. ocellatus (Nigeria), Epl-K = E. pyramidum leakeyi (Kenya).  
  
 Figure 6: Comparison of the performance of each antivenom against a particular species. Equal volumes from 
each of the antivenoms was used as they all were of the same 10ml vial size. Thus the potency is relative to a 
consistent amount of antivenom used by volume not by stated protein content or efficacy claims. The data are 
thus direct head to head comparisons in this regard. Values are means of the ability to proportionally shift a 
curve, with the highest effect being ICP against Ghana which shifted the venom cuve of E. occelatus nearly 
sixty five times over (N=3 with error bars indicating standard deviation). Eca-I = E. carinatus (India), Ecs-P 
= E. c. sochureki (Pakistan), Ecs-U = E. c. sochureki (UAE), Eco-S = E. coloratus (Saudi Arabia), Ejo-S = 
E.jogeri (Senegal), Ele-M = E. leucogaster (Mali), Eoc-G = E. ocellatus (Ghana), Eoc-M = E. ocellatus (Mali), 
Eoc-N = E. ocellatus (Nigeria), Epl-K = E. pyramidum leakeyi (Kenya). 
  
 Figure 7: Ancestral state reconstruction of relative species selectivity for each antivenom where warmer 
colours represent better antivenom cross-reactivity.  Values are normalised N=3 means within an antivenom. 
Bars indicate 95% confidence intervals for the estimate at each node. Note that due to the high dynamicity of 
venom evolution the ranges quickly become broad as one moves down the tree. Phylogenetic tree is based 
upon (Pook et al., 2009; Alencar et al. 2016). 
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